Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.38 |
| ▸ | METAP2 | P50579 | 2/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 7/20 | 0.35 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | ITK | Q08881 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
| ▸ | CHUK | O15111 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17179281 | 0.83 | AHR (0.45) | NOS1METAP2DYRK1AAHRITK | |
| SCHEMBL17422899 | 0.82 | AHR (0.39) | NOS1METAP2DYRK1AAHR | |
| SCHEMBL17422721 | 0.79 | DAO (0.42) | NOS1METAP2DYRK1AIDO1AHR | |
| SCHEMBL17422789 | 0.79 | GPR84 (0.43) | IDO1 | |
| SCHEMBL17422839 | 0.77 | NOS1 (0.36) | NOS1METAP2DYRK1AIDO1ITK | |
| SCHEMBL17433389 | 0.77 | CYP19A1 (0.45) | NOS1METAP2DYRK1AIDO1AHR | |
| SCHEMBL17422813 | 0.77 | DAO (0.42) | IDO1AHR | |
| SCHEMBL22128280 | 0.73 | IDO1 (0.48) | NOS1METAP2DYRK1AIDO1ITK | |
| SCHEMBL8309165 | 0.70 | AHR (0.42) | NOS1METAP2DYRK1AAHRITK | |
| SCHEMBL30920844 | 0.70 | LOXL2 (0.58) | NOS1METAP2DYRK1AAHRITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170216252-A1 | ANTI-BACTERIAL PYRUVATE KINASE MODULATOR COMPOUNDS, COMPOSITIONS, USES AND METHODS | SIMON FRASER UNIVERSITY (CA) | 2017-08-03 | — | — | US | disclosed |
| US-20170216252-A1 | ANTI-BACTERIAL PYRUVATE KINASE MODULATOR COMPOUNDS, COMPOSITIONS, USES AND METHODS | SIMON FRASER UNIVERSITY (CA) | 2017-08-03 | — | — | US | disclosed |
| WO-2016004513-A1 | ANTI-BACTERIAL PYRUVATE KINASE MODULATOR COMPOUNDS, COMPOSITIONS, USES AND METHODS | SIMON FRASER UNIVERSITY (CA) | 2016-01-14 | — | — | WO | disclosed |
| WO-2016004513-A1 | ANTI-BACTERIAL PYRUVATE KINASE MODULATOR COMPOUNDS, COMPOSITIONS, USES AND METHODS | SIMON FRASER UNIVERSITY (CA) | 2016-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216252-A1 | ANTI-BACTERIAL PYRUVATE KINASE MODULATOR COMPOUNDS, COMPOSITIONS, USES AND METHODS | PDK1, PDK3, PDK2 | NOS1 1495/4885METAP2 2548/4885DYRK1A 1811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.